Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer.

ABSTRACT:

Background

Data from meta-analyses support the use of induction or adjuvant platinum-based chemotherapy for locally advanced non-small cell lung cancers (NSCLCs). This phase 2 study assessed the role of induction cisplatin and docetaxel followed by surgery in patients with resectable stage I to III NSCLCs, followed by 12 months of adjuvant erlotinib.

Methods

Patients with resectable stage I to III NSCLCs received cisplatin 80 mg/m², docetaxel 75 mg/m² every 21 days for 3 cycles, followed by surgery, followed by adjuvant erlotinib for 12 months. The primary endpoint included safety. Long-term efficacy outcomes and exploratory analysis of intermediary endpoints are also reported (NCT00254384).

Results

Forty-seven eligible patients received a median

SUBMITTER: Cascone T 

PROVIDER: S-EPMC5783769 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature